Search results for "cardiovascular disease"

showing 10 items of 2332 documents

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.

2016

Peroxisome proliferator-activated receptors (PPAR) are implicated in the pathology of several metabolic diseases including obesity, diabetes, and atherosclerosis. PPAR agonists exert multiple lipid modifying actions which are beneficial to the prevention of atherosclerosis. Such benefits in lipid lowering actions include improvements in atherogenic dyslipidemia that seems to be particularly expressed in individuals at higher cardiovascular (CV) risk. In addition, the favorable effects of PPAR agonists on different cardio-metabolic parameters are established in several metabolic conditions, such as diabetes mellitus, insulin resistance, and heightened systemic inflammation. The goal of this …

0301 basic medicinePeroxisome Proliferator-Activated Receptormedicine.medical_specialtyPeroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptor030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationPPAR agonist03 medical and health sciences0302 clinical medicineInsulin resistanceRisk FactorsCardiovascular DiseaseInternal medicineDiabetes mellitusDrug DiscoverymedicineAnimalsHumansDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationClinical Trials as TopicHypolipidemic Agentmedicine.diagnostic_testAnimalbusiness.industryRisk FactorAtherogenic dyslipidemiaCardiovascular riskmedicine.diseaseAtherosclerosisObesityThiazoles030104 developmental biologyEndocrinologyDyslipidemiachemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)medicine.symptomLipid profilebusinessHumanLipoproteinCurrent pharmaceutical design
researchProduct

Inorganic nitrite and nitrate in cardiovascular therapy: A better alternative to organic nitrates as nitric oxide donors?

2017

In 1867 the organic nitrite, amyl nitrite, was introduced as a therapeutic agent in the treatment of angina pectoris and was later substituted by the organic nitrate nitroglycerin (NTG). Despite having a highly potent vasodilator capacity in veins>coronary arteries>arterioles, the vasodilator effects NTG are rapidly attenuated by the development of nitrate tolerance. We and others established that NTG treatment stimulates the production of reactive oxygen species such as superoxide and peroxynitrite with subsequent marked attenuation of the NTG vasodilator potency. The nitrite anion (NO2-) has more recently been characterized to possess novel pharmacotherapeutic actions such as modulation o…

0301 basic medicinePhysiologyVasodilator AgentsVasodilation030204 cardiovascular system & hematologyPharmacologyNitric OxideCardiovascular SystemNitric oxideAngina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNitratemedicineAnimalsHumansNitric Oxide DonorsNitriteNitritesPharmacologyNitratesSuperoxidemedicine.diseaseVasodilation030104 developmental biologychemistryBiochemistryCardiovascular DiseasesMolecular MedicineAmyl nitritePeroxynitriteSignal Transductionmedicine.drugVascular Pharmacology
researchProduct

Effects of air pollution particles (ultrafine and fine particulate matter) on mitochondrial function and oxidative stress – Implications for cardiova…

2020

Environmental pollution is a major cause of global mortality and burden of disease. All chemical pollution forms together may be responsible for up to 12 million annual excess deaths as estimated by the Lancet Commission on pollution and health as well as the World Health Organization. Ambient air pollution by particulate matter (PM) and ozone was found to be associated with an all-cause mortality rate of up to 9 million in the year 2015, with the majority being of cerebro- and cardiovascular nature (e.g. stroke and ischemic heart disease). Recent evidence suggests that exposure to airborne particles and gases contributes to and accelerates neurodegenerative diseases. Especially, airborne t…

0301 basic medicinePollutionmedia_common.quotation_subjectBiophysicsAir pollutionEnvironmental pollutionDiseasemedicine.disease_causeBiochemistry03 medical and health sciencesEnvironmental healthMedicineAnimalsHumansEnvironmental risk factorsNeurodegenerationMolecular Biologymedia_commonMitochondrial damage and dysfunctionAir Pollutants030102 biochemistry & molecular biologybusiness.industryMortality rateNeurodegenerationNeurodegenerative DiseasesParticulatesmedicine.diseaseCardiovascular diseaseMitochondriaOxidative Stress030104 developmental biologyCardiovascular DiseasesAmbient air pollution; Cardiovascular disease; Environmental risk factors; Mitochondrial damage and dysfunction; Neurodegeneration; Particulate matter; Air Pollutants; Animals; Cardiovascular Diseases; Humans; Mitochondria; Neurodegenerative Diseases; Oxidative Stress; Particulate MatterParticulate MatterAmbient air pollutionbusinessOxidative stress
researchProduct

Emerging Roles of RNA 3′-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders

2020

A crucial feature of gene expression involves RNA processing to produce 3′ ends through a process termed 3′ end cleavage and polyadenylation (CPA). This ensures the nascent RNA molecule can exit the nucleus and be translated to ultimately give rise to a protein which can execute a function. Further, alternative polyadenylation (APA) can produce distinct transcript isoforms, profoundly expanding the complexity of the transcriptome. CPA is carried out by multi-component protein complexes interacting with multiple RNA motifs and is tightly coupled to transcription, other steps of RNA processing, and even epigenetic modifications. CPA and APA contribute to the maintenance of a multitude of dive…

0301 basic medicinePolyadenylationcardiovascular disorderslcsh:QR1-502ReviewComputational biologyBiologyPolyadenylationCleavage (embryo)Biochemistrylcsh:MicrobiologyTranscriptome03 medical and health sciences0302 clinical medicineTranscription (biology)NeoplasmsGene expressionHumansDirectionalitycancerheterocyclic compoundsEpigeneticsMolecular BiologyRNA Cleavagediseasetherapyalternative polyadenylationRNAfood and beveragesNeurodegenerative Diseases3′ end processing030104 developmental biologyCardiovascular Diseases030220 oncology & carcinogenesisneurodegenerative disorderscardiovascular systemRNAbiomarkercleavage and polyadenylationBiomolecules
researchProduct

Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases

2018

Background: Polyphenols are bioactive compounds that can be found mostly in foods like fruits, cereals, vegetables, dry legumes, chocolate and beverages such as coffee, tea and wine. They are extensively used in the prevention and treatment of cardiovascular disease (CVD) providing protection against many chronic illnesses. Their effects on human health depend on the amount consumed and on their bioavailability. Many studies have demonstrated that polyphenols have also good effects on the vascular system by lowering blood pressure, improving endothelial function, increasing antioxidant defences, inhibiting platelet aggregation and low-density lipoprotein oxidation, and reducing inflammator…

0301 basic medicinePolyphenolcardiovascular risklignanAntioxidantmedicine.medical_treatmentInflammationPharmacologystilbenesmedicine.disease_cause03 medical and health sciencespreventionDiabetes mellitusDrug DiscoveryHumansMedicineAnimalsflavonoidLipoprotein oxidationEndothelial dysfunctionpolyphenolsPharmacologytherapytherapy.030109 nutrition & dieteticsphenolic acidbusiness.industrylignansfood and beveragesmedicine.diseasestilbeneCardiovascular DiseasesPolyphenolflavonoidspolyphenols; flavonoids; lignans; stilbenes; phenolic acids; prevention; therapy; cardiovascular riskmedicine.symptombusinessphenolic acidsOxidative stressLipoprotein
researchProduct

Predictive validity of the risk SCORE model in a Mediterranean population with dyslipidemia.

2019

Background and aims: Cholesterol treatment for the primary prevention of cardiovascular disease is based on cardiovascular risk, as assessed by the SCORE (Systematic COronary Risk Evaluation) scale. This study aimed to assess the predictive value and clinical utility of the SCORE scale for preventing cardiovascular events and all-cause mortality in people with dyslipidemia and no lipid-lowering treatment. Methods: Patients with dyslipidemia and no lipid-lowering treatment were included from the ESCARVAL-RISK cohort. Cardiovascular risk was calculated by means of the SCORE scale. All deaths and cardiovascular events were recorded for up to five years of follow-up. We calculated sensitivity, …

0301 basic medicinePredictive validityAdultMalemedicine.medical_specialtyTime FactorsPopulationHypercholesterolemia030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicineDiabetes mellitusSCOREmedicineHumansProspective StudiesRegistrieseducationAgededucation.field_of_studyFramingham Risk Scorebusiness.industryReproducibility of ResultsMiddle Agedmedicine.diseaseCardiovascular diseaseCardiovascular riskPrognosis030104 developmental biologyCardiovascular DiseasesSpainCohortDisease ProgressionFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemiaKidney diseaseAtherosclerosis
researchProduct

Sterol 27-hydroxylase polymorphism significantly associates with shorter telomere, higher cardiovascular and type-2 diabetes risk in obese subjects

2018

Background/objectivesThe pathologic relationship linking obesity and lipid dismetabolism with earlier onset of aging-related disorders, including cardiovascular disease (CVD) and type-2 diabetes (T2D), is not fully elucidate. Chronic inflammatory state, in obese individuals, may accelerate cellular aging. However, leukocyte telomere length (LTL), the cellular biological aging indicator, is elusively linked with obesity. Recent studies indicate that sterol 27-hydroxylase (CYP27A1) is an emerging antiatherogenic enzyme, that, by converting extrahepatic cholesterol to 27-hydroxycholesterol, facilitates cholesterol removal via high-density lipoprotein-cholesterol (HDL-C). We tested the hypothes…

0301 basic medicinePremature agingmedicine.medical_specialtyGenotypingHDLEndocrinology Diabetes and MetabolismType 2 diabetesOverweightCardiovascular diseases; Cholesterol; Diabetes mellitus type 2; Genotyping; HDL; Insulin sensitive obese; Obesity; Telomere shortening; Endocrinology Diabetes and Metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyInsulin sensitive obeseTelomere shortening03 medical and health scienceschemistry.chemical_compoundInsulin resistanceWaist–hip ratioDiabetes mellitus type 2EndocrinologyInternal medicineDiabetes mellitusmedicineGlucose homeostasisObesityOriginal Research2. Zero hungerlcsh:RC648-665business.industrymedicine.disease3. Good healthDiabetes and Metabolism030104 developmental biologyEndocrinologyCardiovascular diseasesCholesterolchemistryGlycated hemoglobinmedicine.symptombusiness
researchProduct

Searching for Chymase Inhibitors among Chamomile Compounds Using a Computational-Based Approach

2018

Inhibitors of chymase have good potential to provide a novel therapeutic approach for the treatment of cardiovascular diseases. We used a computational approach based on pharmacophore modeling, docking, and molecular dynamics simulations to evaluate the potential ability of 13 natural compounds from chamomile extracts to bind chymase enzyme. The results indicated that some chamomile compounds can bind to the active site of human chymase. In particular, chlorogenic acid had a predicted binding energy comparable or even better than that of some known chymase inhibitors, interacted stably with key amino acids in the chymase active site, and appeared to be more selective for chymase than other …

0301 basic medicineProteaseschlorogenic acidlcsh:QR1-502030204 cardiovascular system & hematologyMolecular Dynamics SimulationCrystallography X-RayLigandsBiochemistrylcsh:MicrobiologyArticleSerine03 medical and health sciences0302 clinical medicineChymasesCatalytic DomainHumanschamomilecardiovascular diseases; chamomile; chlorogenic acid; chymase; docking; matricin; molecular dynamics simulations; pharmacophore; Biochemistry; Molecular BiologyEnzyme InhibitorsMolecular Biologychymasechemistry.chemical_classificationBinding SitesbiologypharmacophoreChymaseActive sitemolecular dynamics simulationsmatricinAmino acidcardiovascular diseasesMolecular Docking Simulation030104 developmental biologyEnzymechemistryBiochemistryDocking (molecular)dockingbiology.proteinPharmacophoreBiomolecules
researchProduct

Is proteomics of value in cardiovascular risk assessment?

2019

Purpose of review To briefly summarize recently published evidence in the field of cardiovascular proteomics, focusing on its ability to improve cardiovascular risk stratification and critically discussing still open and burning issues and future perspectives of proteomics research. Recent findings Several epidemiological studies have demonstrated an improvement in cardiovascular risk prediction beyond traditional risk factors by adding novel biomarkers, identified by both discovery and targeted proteomics. However, only a moderate improvement in risk discrimination over clinical variables was observed. Moreover, despite different outcomes there was also a strong overlap of identified candi…

0301 basic medicineProteomicsClinical variablesGrowth Differentiation Factor 15Endocrinology Diabetes and MetabolismDisease030204 cardiovascular system & hematologyProteomicsBioinformaticsRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsGeneticsMedicineAnimalsHumansBiomarker discoveryNatriuretic PeptidesMolecular BiologyNutrition and Dieteticsbusiness.industryInterleukinsCell BiologyTargeted proteomics030104 developmental biologyC-Reactive ProteinCardiovascular DiseasesRisk stratificationMetalloproteasesCardiology and Cardiovascular MedicinebusinessRisk assessmentBiomarkersCurrent opinion in lipidology
researchProduct

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

2017

The direct oral anticoagulants (DOACs) have been compared with parenteral anticoagulants and vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) in several robust studies. DOACs have shown similar efficacy in preventing recurrent VTE and significant reductions in critical site (intracranial) bleeding, fatal bleeding, major and nonmajor bleeding. Warfarin and other VKAs are not dead as treatment modalities for VTE. A better way to describe the current situation is to use a boxing expression, “down but not out.” VKAs and parenteral anticoagulants still have a role to play in the management of VTE in several clinical settings. In indications where DOACs can be used, …

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyAdministration OralClinical settingsVitamin kCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineOral anticoagulationCerebral Hemorrhagebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismSafety profile030104 developmental biologyTreatment modalityvenous thromboembolism oral anticoagulation warfarin non-VKA oral anticoagulants safety efficacy030220 oncology & carcinogenesisWarfarinbusinessVenous thromboembolismmedicine.drug
researchProduct